Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin®)

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab...

Full description

Saved in:
Bibliographic Details
Main Authors: Choi, Young Il, Lee, Seung Hyun, Ahn, Byung Kwon, Baek, Sung Uhn, Park, Seun Ja, Kim, Yang Soo, Shin, Seong Hoon
Format: Artigo
Language:Inglês
Published: Korean Cancer Association 2008
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2699085/
https://ncbi.nlm.nih.gov/pubmed/19688063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2008.40.1.33
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items